生物可吸收血管支架与药物洗脱支架治疗冠状动脉疾病的两年结局:一项Meta分析
该Meta分析纳入5项研究共2360例患者,比较依维莫司洗脱生物可吸收血管支架(BVS)与第二代药物洗脱支架(DES)在随访2年时的临床结局。结果显示BVS与更高的器械相关复合事件、靶血管心肌梗死和确定性支架内血栓发生率相关,全因死亡和靶病变血运重建无显著差异。作者认为BVS可能与较差的长期临床结局相关,鼓励随机临床试验尽快报告长期安全性和有效性结局。
要点
- 随访2年,BVS组器械相关复合事件发生率6.9%,DES组4.5%,OR=1.53(95%CI 1.06-2.23;p=0.02)。
- BVS组确定性支架内血栓发生率2.1%,DES组0.6%,OR=3.39(95%CI 1.46-7.88;p=0.005)。
- 全因死亡(OR=0.86;95%CI 0.26-2.81;p=0.80)和靶病变血运重建(OR=1.44;95%CI 0.81-2.54;p=0.21)两组无显著差异。
核心结论
- BVS可能与较差的长期临床结局相关,随机临床试验被鼓励尽快报告长期安全性和有效性结局,并识别BVS相比DES的不良事件预测因素。
研究设计与样本
- 检索截至2016年10月的在线数据库,纳入比较BVS与DES并报告随访2年结局的研究,进行Meta分析,计算随机效应模型OR。
- 共纳入5项研究、2360例患者。
主要发现
- 随访2年,BVS组器械相关复合事件发生率6.9%,DES组4.5%,OR=1.53(95%CI 1.06-2.23;p=0.02),绝对风险增加2.4%,相对风险增加53%。
- BVS组靶血管心肌梗死发生率4%,DES组1.8%,OR=1.94(95%CI 1.02-3.67;p=0.04),绝对风险增加2.2%,相对风险增加122%。
- BVS组确定性支架内血栓发生率2.1%,DES组0.6%,OR=3.39(95%CI 1.46-7.88;p=0.005),绝对风险增加1.5%,相对风险增加250%。
- 全因死亡(OR=0.86;95%CI 0.26-2.81;p=0.80)和靶病变血运重建(OR=1.44;95%CI 0.81-2.54;p=0.21)两组无显著差异。
关键数值与推荐
- 器械相关复合事件定义为心源性死亡、靶血管心肌梗死和缺血驱动的靶病变血运重建的复合终点。
- 结局指标包括器械相关复合事件、全因死亡、确定性支架内血栓、靶血管心肌梗死和靶病变血运重建。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Data regarding long-term clinical outcomes with everolimus-eluting bioresorbable vascular scaffold (BVS) versus second-generation drug-eluting stents (DES) are scarce. METHODS: We searched online databases until October 2016 for studies comparing BVS versus DES reporting outcomes at 2 years of follow-up. We performed a meta-analysis comparing BVS with DES across the spectrum of coronary artery disease (CAD). Random effects model OR was calculated for outcomes of interest including device-oriented composite events (DOCE; defined as composite of cardiac mortality, target vessel myocardial infarction (TV-MI), and ischaemia-driven target lesion revascularisation (TLR)), all-cause mortality, definite stent thrombosis, TV-MI and TLR. RESULTS: A total of 2360 patients enrolled in five studies met criteria for inclusion in this analysis. At 2 years, BVS was associated with higher rates of DOCE (6.9% vs 4.5%, OR=1.53; 95% CI 1.06 to 2.23; p=0.02), absolute risk increase (ARI) 2.4%, relative risk increase (RRI) 53%, TV-MI (4% vs 1.8%, OR=1.94; 95% CI 1.02 to 3.67; p=0.04), ARI 2.2%, RRI 122% and definite stent thrombosis (2.1% vs 0.6%, OR=3.39; 95% CI 1.46 to 7.88; p=0.005), ARI 1.5%, RRI 250% compared with DES. No differences in all-cause mortality (OR=0.86; 95% CI 0.26 to 2.81; p=0.80) and TLR (OR=1.44; 95% CI 0.81 to 2.54; p=0.21) were observed between both groups. CONCLUSIONS: BVS may be associated with worse long-term clinical outcomes compared with DES. Randomised clinical trials are encouraged to expeditiously report long-term safety and efficacy outcomes and identify predictors of adverse events with BVS compared with DES.
引用
- Nairooz R, Saad M, Sardar P, et al. Two-year outcomes of bioresorbable vascular scaffold versus drug-eluting stents in coronary artery disease: a meta-analysis. Heart. 2017. PMID: 28115471. doi:10.1136/heartjnl-2016-310886
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。